Eli Lilly's stock has dropped, with reports citing disappointing initial sales data for a new drug as a possible factor. The extent of the decline is unclear, with some outlets reporting a 4% slide and others a 6% drop. Despite the recent decline, the stock had previously reached a record high, although some analysts have expressed doubts about the company's long-term trajectory.